Literature DB >> 196861

Impairment of drug metabolism in patients with liver cancer.

E A Sotaniemi, R O Pelkonen, R E Mokka, R Huttunen, E Viljakainen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 196861     DOI： 10.1111/j.1365-2362.1977.tb01604.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN： 0014-2972            Impact factor:   4.686


× No keyword cloud information.
  13 in total

1.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.

Authors:  E A Sotaniemi; R O Pelkonen; M Puukka
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

3.  Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.

Authors:  M M Homeida; T K Daneshmend; E M Ali; A G Yousif-Elkadaru; B M Arbab
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

4.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

5.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage.

Authors:  E A Sotaniemi; O T Hokkanen; J T Ahokas; R O Pelkonen; J Ahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

Review 7.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse.

Authors:  G Powis; R N Harris; P J Basseches; K S Santone
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Changes in toxic and antitumor properties of ftorafur by induction or inhibition of the microsomal enzymes activity.

Authors:  G A Belitsky; V M Bukhman; I A Konopleva
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker.

Authors:  S Säkö; E A Sotaniemi; M Anttila
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.